SOURCE: Salus Labs

December 22, 2010 08:30 ET

Salus Labs International Announces Initial Financing

LAS VEGAS, NV--(Marketwire - December 22, 2010) - Salus Labs International, Inc. (PINKSHEETS: IPEX) is pleased to announce that the first round of financing by a Private Investment Fund has been secured and received. This private infusion of capital now secures Salus Labs' ability to move to the next phase of product development. Although originally set for release in the last quarter of 2010, additional development as well as market research was conducted to better ensure a successful introduction into the market place. Salus' first product, a revolutionary anti-aging compound, is expected to be released in the first quarter 2011.

The company intends to develop, produce, and market high-quality nutritional supplements and anti-aging products. Salus Labs has initially defined its target market as the over-35 age group. Generally, this population values good health, and will become loyal customers to high-quality nutrition and fitness products that produce the desired results. The company will focus on the issues of aging and the sustainment of improved long-term health and fitness. 

To date, while clinical testing of several products continues, the anti-aging product to be introduced in the coming months has shown remarkable results. Another product undergoing testing will focus on the vast number of people world-wide who are either directed to or prefer to lower body weight and/or cholesterol levels.

Art Wenzlaff, CEO, indicates, "Our company is in the right place at the right time for major contributions to the health and fitness industry. Our intention is to produce unique, one-of-a-kind products which will create their own demand. 'Better Living Through Chemistry,' the credo of our scientific staff, is the guide-post to our mission of improving customer quality of life. Through the anticipated success of these products corporate growth and shareholder value will significantly improve. Securing this initial funding allows our company to return to our original production schedule."

The company expects to continue its plans previously announced to:

  • Provide additional information about products as they are released. 

  • The company intends to become fully reporting as quickly as possible. 

  • A corporate web site is expected to be developed and operational during first quarter of 2011. The company intends to keep the site current, transparent, and provide an effective means for communications between management, its shareholders, and the investment community.  

About Salus Labs, International, Inc.

Salus Labs, International, Inc., a Nevada Corporation, is focused primarily on the research, development, production, and marketing of high-quality nutritional supplements and anti-aging products. It currently trades on the OTC Markets as IPEX.PK.

Notice on Forward-Looking Statements:
The matters set forth in this press release may contain forward-looking statements regarding Salus Labs and its business within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date on which they are made and Salus Labs undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Statements are subject to risks and uncertainties that may cause actual results to differ materially. 

Contact Information

  • For Information Contact:
    Investor relations
    Gary Patterson
    ir@saluslabs.com
    714-369-2933